Non-coding RNAs: key players in cardiac disease.
Cardiology
CircRNA
Genome
Heart failure
LncRNA
MicroRNA
Non-coding RNA
Journal
The Journal of physiology
ISSN: 1469-7793
Titre abrégé: J Physiol
Pays: England
ID NLM: 0266262
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
30
04
2019
accepted:
29
05
2019
pubmed:
11
7
2019
medline:
16
2
2021
entrez:
11
7
2019
Statut:
ppublish
Résumé
Molecular mechanisms underlying heart failure (HF) are only partly understood. Non-coding RNAs (ncRNAs) have been reported to control function and signalling routes in the myocardium. As ncRNAs such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs) or circular RNAs (circRNAs) can be selectively targeted via pharmacological approaches, this opens new avenues for diagnostic and therapeutic approaches. Here, we review the main ncRNA classes and how they influence cardiac biology. In addition we provide insight into the role of ncRNAs in chemotherapy-induced cardiac dysfunction. To provide a better understanding of ncRNAs in cardiovascular biology we present an outlook on specialized functions such as chromatin remodelling, biomarker potential and the recently discovered ncRNA-derived micropeptides.
Substances chimiques
MicroRNAs
0
RNA, Circular
0
RNA, Long Noncoding
0
RNA, Untranslated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2995-3003Subventions
Organisme : ERC
ID : LONGHEART
Pays : International
Organisme : ERANet
ID : Expert
Pays : International
Informations de copyright
© 2019 The Authors. The Journal of Physiology © 2019 The Physiological Society.
Références
Anderson DM, Anderson KM, Chang C-L, Makarewich CA, Nelson BR, McAnally JR, Kasaragod P, Shelton JM, Liou J, Bassel-Duby R & Olson EN (2015). A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell 160, 595-606.
Bánfai B, Jia H, Khatun J, Wood E, Risk B, Gundling WE, Kundaje A, Gunawardena HP, Yu Y, Xie L, Krajewski K, Strahl BD, Chen X, Bickel P, Giddings MC, Brown JB & Lipovich L (2012). Long noncoding RNAs are rarely translated in two human cell lines. Genome Res 22, 1646-1657.
Bang C, Batkai S, Dangwal S, Gupta SK, Foinquinos A, Holzmann A, Just A, Remke J, Zimmer K, Zeug A, Ponimaskin E, Schmiedl A, Yin X, Mayr M, Halder R, Fischer A, Engelhardt S, Wei Y, Schober A, Fiedler J & Thum T (2014). Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 124, 2136-2146.
Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233.
Beermann J, Piccoli MT, Viereck J & Thum T (2016). Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev 96, 1297-1325.
Boeckel JN, Jae N, Heumuller AW, Chen W, Boon RA, Stellos K, Zeiher AM, John D, Uchida S & Dimmeler S (2015). Identification and characterization of hypoxia-regulated endothelial circular RNA. Circ Res 117, 884-890.
Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tonlorenzi R & Willard HF (1991). A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature 349, 38-44.
Brown CJ, Hendrich BD, Rupert JL, Lafrenière RG, Xing Y, Lawrence J & Willard HF (1992). The human XIST gene: Analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. Cell 71, 527-542.
Cai X & Cullen BR (2007). The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA 13, 313-316.
Cheng HS, Besla R, Li A, Chen Z, Shikatani EA, Nazari-Jahantigh M, Hammoutene A, Nguyen MA, Geoffrion M, Cai L, Khyzha N, Li T, MacParland SA, Husain M, Cybulsky MI, Boulanger CM, Temel RE, Schober A, Rayner KJ, Robbins CS & Fish JE (2017). Paradoxical suppression of atherosclerosis in the absence of microRNA-146a. Circ Res 121, 354-367.
Cocquerelle C, Mascrez B, Hétuin D & Bailleul B (1993). Mis-splicing yields circular RNA molecules. FASEB J 7, 155-160.
Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Shiekhattar R, Gingeras TR, Hubbard TJ, Notredame C, Harrow J & Guigó R (2012). The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome research 22, 1775-1789. https://doi.org/10.1101/gr.132159.111.
Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, Xue C, Marinov GK, Khatun J, Williams BA, Zaleski C, Rozowsky J, Röder M, Kokocinski F, Abdelhamid RF, Alioto T, Antoshechkin I, Baer MT, Bar NS, Batut P, Bell K, Bell I, Chakrabortty S, Chen X, Chrast J, Curado J, Derrien T, Drenkow J, Dumais E, Dumais J, Duttagupta R, Falconnet E, Fastuca M, Fejes-Toth K, Ferreira P, Foissac S, Fullwood MJ, Gao H, Gonzalez D, Gordon A, Gunawardena H, Howald C, Jha S, Johnson R, Kapranov P, King B, Kingswood C, Luo OJ, Park E, Persaud K, Preall JB, Ribeca P, Risk B, Robyr D, Sammeth M, Schaffer L, See L-H, Shahab A, Skancke J, Suzuki AM, Takahashi H, Tilgner H, Trout D, Walters N, Wang H, Wrobel J, Yu Y, Ruan X, Hayashizaki Y, Harrow J, Gerstein M, Hubbard T, Reymond A, Antonarakis SE, Hannon G, Giddings MC, Ruan Y, Wold B, Carninci P, Guigó R & Gingeras TR (2012). Landscape of transcription in human cells. Nature 489, 101-108.
Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C, Hofmann W-K, Zeiher AM & Dimmeler S (2010). Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 115, 4944-4950.
Eskiw CH, Rapp A, Carter DRF & Cook PR (2008). RNA polymerase II activity is located on the surface of protein-rich transcription factories. J Cell Sci 121, 1999-2007.
Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S & Giacca M (2012). Functional screening identifies miRNAs inducing cardiac regeneration. Nature 492, 376-381.
Ewer MS & Ewer SM (2010). Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 7, 564-575.
Ewer MS & Lippman SM (2005). Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity., J Clin Oncol 23, 2900-2902.
Fiedler J, Breckwoldt K, Remmele CW, Hartmann D, Dittrich M, Pfanne A, Just A, Xiao K, Kunz M, Muller T, Hansen A, Geffers R, Dandekar T, Eschenhagen T & Thum T (2015). Development of long noncoding RNA-based strategies to modulate tissue vascularization. J Am Coll Cardiol 66, 2005-2015.
Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, Galuppo P, Kneitz S, Pena JT, Sohn-Lee C, Loyer X, Soutschek J, Brand T, Tuschl T, Heineke J, Martin U, Schulte-Merker S, Ertl G, Engelhardt S, Bauersachs J & Thum T (2011). MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124, 720-730.
Friedman RC, Farh KK-H, Burge CB & Bartel DP (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19, 92-105.
Frith MC, Pheasant M & Mattick JS (2005). The amazing complexity of the human transcriptome. Eur J Hum Genet 13, 894-897.
Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE, Swain SM, Jeong J-H, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP & Wolmark N (2017). Long-term follow-up of cardiac function and quality of life for patients in NSABP Protocol B-31/NRG oncology: A randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. J Clin Oncol 35, 3942-3948.
Gregory TR (2004). Macroevolution, hierarchy theory, and the C-value enigma. Paleobiology 30, 179-202.
Griffiths-Jones S (2004). The microRNA Registry. Nucleic Acids Res 32, D109-D111.
Gupta SK, Garg A, Bär C, Chatterjee S, Foinquinos A, Milting H, Streckfuß-Bömeke K, Fiedler J & Thum T (2018). Quaking inhibits doxorubicin-mediated cardiotoxicity through regulation of cardiac circular RNA expression. Circ Res 122, 246-254.
Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, Castermans K, Malvaux L, Lambert V, Thiry M, Sliwa K, Noel A, Martial JA, Hilfiker-Kleiner D & Struman I (2013). MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 123, 2143-2154.
Han P, Li W, Lin C-H, Yang J, Shang C, Nuernberg ST, Jin KK, Xu W, Lin C-Y, Lin C-J, Xiong Y, Chien H, Zhou B, Ashley E, Bernstein D, Chen P-S, Chen H-SV, Quertermous T & Chang C-P (2014). A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514, 102-106.
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK & Kjems J (2013). Natural RNA circles function as efficient microRNA sponges. Nature 495, 384-388.
Hartmann D, Fiedler J, Sonnenschein K, Just A, Pfanne A, Zimmer K, Remke J, Foinquinos A, Butzlaff M, Schimmel K, Maegdefessel L, Hilfiker-Kleiner D, Lachmann N, Schober A, Froese N, Heineke J, Bauersachs J, Batkai S & Thum T (2016). MicroRNA-based therapy of GATA2-deficient vascular disease. Circulation 134, 1973-1990.
Heggermont WA, Papageorgiou AP, Quaegebeur A, Deckx S, Carai P, Verhesen W, Eelen G, Schoors S, van Leeuwen R, Alekseev S, Elzenaar I, Vinckier S, Pokreisz P, Walravens AS, Gijsbers R, van den Haute C, Nickel A, Schroen B, van Bilsen M, Janssens S, Maack C, Pinto Y, Carmeliet P & Heymans S (2017). Inhibition of microRNA-146a and overexpression of its target dihydrolipoyl succinyltransferase protect against pressure overload-induced cardiac hypertrophy and dysfunction. Circulation 136, 747-761.
Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, Dalby CM, Robinson K, Stack C, Latimer PA, Hare JM, Olson EN & van Rooij E (2012). Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 110, 71-81.
Iborra FJ, Pombo A, Jackson DA & Cook PR (1996). Active RNA polymerases are localized within discrete transcription "factories' in human nuclei. J Cell Sci 109, 1427-1436.
Jakobi T, Czaja-Hasse LF, Reinhardt R & Dieterich C (2016). Profiling and validation of the circular RNA repertoire in adult murine hearts. Genomics Proteomics Bioinformatics 14, 216-223.
Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA & Hodges MR (2013). Treatment of HCV infection by targeting microRNA. N Engl J Med 368, 1685-1694.
Kim T-K, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, Harmin DA, Laptewicz M, Barbara-Haley K, Kuersten S, Markenscoff-Papadimitriou E, Kuhl D, Bito H, Worley PF, Kreiman G & Greenberg ME (2010). Widespread transcription at neuronal activity-regulated enhancers. Nature 465, 182-187.
Kozomara A, Birgaoanu M & Griffiths-Jones S (2019). miRBase: from microRNA sequences to function. Nucleic Acids Res 47, D155-D162.
Kozomara A & Griffiths-Jones S (2014). miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42, D68-D73.
Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, Lemesle G, de Groote P, Pinet F & Thum T (2014). Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res 114, 1569-1575.
Lai F, Orom UA, Cesaroni M, Beringer M, Taatjes DJ, Blobel GA & Shiekhattar R (2013). Activating RNAs associate with Mediator to enhance chromatin architecture and transcription. Nature 494, 497-501.
Lee RC, Feinbaum RL & Ambros V (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854.
Lindow M & Kauppinen S (2012). Discovering the first microRNA-targeted drug. J Cell Biol 199, 407-412.
Lipshultz SE, Alvarez JA & Scully RE (2008). Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94, 525-533.
Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE & Sanders SP (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324, 808-815.
Lu L, Sun K, Chen X, Zhao Y, Wang L, Zhou L, Sun H & Wang H (2013). Genome-wide survey by ChIP-seq reveals YY1 regulation of lincRNAs in skeletal myogenesis. EMBO J 32, 2575-2588.
McHugh CA, Chen C-K, Chow A, Surka CF, Tran C, McDonel P, Pandya-Jones A, Blanco M, Burghard C, Moradian A, Sweredoski MJ, Shishkin AA, Su J, Lander ES, Hess S, Plath K & Guttman M (2015). The Xist lncRNA interacts directly with SHARP to silence transcription through HDAC3. Nature 521, 232-236.
Materazzo C, Massimino M, Schiavello E, Podda M, Gandola L, Cefalo G, Catania S, Meazza C, Moschetti I & Terenziani M (2017). Clinical and subclinical cardiac late effects in pediatric Hodgkin's lymphoma survivors. Tumori 103, 566-571.
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, Le Noble F & Rajewsky N (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333-338.
Memczak S, Papavasileiou P, Peters O & Rajewsky N (2015). Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood. PLoS One 10, e0141214.
Micheletti R, Plaisance I, Abraham BJ, Sarre A, Ting C-C, Alexanian M, Maric D, Maison D, Nemir M, Young RA, Schroen B, González A, Ounzain S & Pedrazzini T (2017). The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med 9, eaai9118.
Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN & van Rooij E (2011). Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124, 1537-1547.
Mousavi K, Zare H, Dell'orso S, Grontved L, Gutierrez-Cruz G, Derfoul A, Hager GL & Sartorelli V (2013). eRNAs promote transcription by establishing chromatin accessibility at defined genomic loci. Mol Cell 51, 606-617.
Nelson BR, Makarewich CA, Anderson DM, Winders BR, Troupes CD, Wu F, Reese AL, McAnally JR, Chen X, Kavalali ET, Cannon SC, Houser SR, Bassel-Duby R & Olson EN (2016). A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. Science 351, 271-275.
Nigro JM, Cho KR, Fearon ER, Kern SE, Ruppert JM, Oliner JD, Kinzler KW & Vogelstein B (1991). Scrambled exons. Cell 64, 607-613.
Ørom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q, Guigo R & Shiekhattar R (2010). Long noncoding RNAs with enhancer-like function in human cells. Cell 143, 46-58.
Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn L-J, van der Veer E, Raney AK, Hodges MR & Patick AK (2015). In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother 59, 599-608.
Ounzain S, Micheletti R, Arnan C, Plaisance I, Cecchi D, Schroen B, Reverter F, Alexanian M, Gonzales C, Ng SY, Bussotti G, Pezzuto I, Notredame C, Heymans S, Guigó R, Johnson R & Pedrazzini T (2015). CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. J Mol Cell Cardiol 89, 98-112.
Piccoli MT, Gupta SK, Viereck J, Foinquinos A, Samolovac S, Kramer FL, Garg A, Remke J, Zimmer K, Batkai S & Thum T (2017). Inhibition of the cardiac fibroblast-enriched lncRNA Meg3 prevents cardiac fibrosis and diastolic dysfunction. Circ Res 121, 575-583.
Sasaki YTF, Ideue T, Sano M, Mituyama T & Hirose T (2009). MENε/β noncoding RNAs are essential for structural integrity of nuclear paraspeckles. Proc Natl Acad Sci U S A 106, 2525-2530.
Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ & Keefe D (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20, 1215-1221.
Swain SM, Whaley FS & Ewer MS (2003). Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97, 2869-2879.
Tan WLW, Lim BTS, Anene-Nzelu CGO, Ackers-Johnson M, Dashi A, See K, Tiang Z, Lee DP, Chua WW, Luu TDA, Li PYQ, Richards AM & Foo RSY (2017). A landscape of circular RNA expression in the human heart. Cardiovasc Res 113, 298-309.
Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JTR, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J & Engelhardt S (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984.
Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S, Dangwal S, Kumarswamy R, Bang C, Holzmann A, Remke J, Caprio M, Jentzsch C, Engelhardt S, Geisendorf S, Glas C, Hofmann TG, Nessling M, Richter K, Schiffer M, Carrier L, Napp LC, Bauersachs J, Chowdhury K & Thum T (2012). The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 3, 1078.
Viereck J, Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M, Dittrich M, Maetzig T, Zimmer K, Remke J, Just A, Fendrich J, Scherf K, Bolesani E, Schambach A, Weidemann F, Zweigerdt R, de Windt LJ, Engelhardt S, Dandekar T, Batkai S & Thum T (2016). Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med 8, 326ra22.
von Hoff DD, Layard MW, Basa P, Davis HL, von Hoff AL, Rozencweig M & Muggia FM (1979). Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91, 710-717.
Wen Y, Chen R, Zhu C, Qiao H, Liu Y, Ji H, Miao J, Chen L, Liu X & Yang Y (2018). MiR-503 suppresses hypoxia-induced proliferation, migration and angiogenesis of endothelial progenitor cells by targeting Apelin. Peptides 105, 58-65.
Willeit P, Skroblin P, Kiechl S, Fernandez-Hernando C & Mayr M (2016). Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? Eur Heart J 37, 3260-3266.
Willeit P, Skroblin P, Moschen AR, Yin X, Kaudewitz D, Zampetaki A, Barwari T, Whitehead M, Ramirez CM, Goedeke L, Rotllan N, Bonora E, Hughes AD, Santer P, Fernandez-Hernando C, Tilg H, Willeit J, Kiechl S & Mayr M (2017). Circulating microRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes 66, 347-357.
Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J & Mayr M (2010). Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107, 810-817.
Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, Mayr A, Weger S, Schett G, Shah A, Boulanger CM, Willeit J, Chowienczyk PJ, Kiechl S & Mayr M (2012). Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 60, 290-299.
Zhou B, Ma R, Si W, Li S, Xu Y, Tu X & Wang Q (2013). MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett 333, 159-169.